| Ident. | Authors (with country if any) | Title |
|---|
| 000165 (2017) |
Teresa M. Petrella ; Caroline Robert ; Erika Richtig ; Wilson H. Miller ; Giuseppe V. Masucci ; Euan Walpole ; Celeste Lebbe ; Neil Steven ; Mark R. Middleton ; Darcy Hille ; Wei Zhou ; Nageatte Ibrahim ; Jonathan Cebon | Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. |
| 000183 (2017) |
Georgina V. Long ; Axel Hauschild ; Mario Santinami ; Victoria Atkinson ; Mario Mandalà ; Vanna Chiarion-Sileni ; James Larkin ; Marta Nyakas ; Caroline Dutriaux ; Andrew Haydon ; Caroline Robert ; Laurent Mortier ; Jacob Schachter ; Dirk Schadendorf ; Thierry Lesimple ; Ruth Plummer ; Ran Ji ; Pingkuan Zhang ; Bijoyesh Mookerjee ; Jeff Legos ; Richard Kefford ; Reinhard Dummer ; John M. Kirkwood | Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. |
| 000205 (2017) |
Georgina V. Long ; Jeffrey S. Weber ; James Larkin ; Victoria Atkinson ; Jean-Jacques Grob ; Dirk Schadendorf ; Reinhard Dummer ; Caroline Robert ; Ivan Márquez-Rodas ; Catriona Mcneil ; Henrik Schmidt ; Karen Briscoe ; Jean-François Baurain ; F Stephen Hodi ; Jedd D. Wolchok | Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. |
| 000294 (2017) |
Jacob Schachter ; Antoni Ribas ; Georgina V. Long ; Ana Arance ; Jean-Jacques Grob ; Laurent Mortier ; Adil Daud ; Matteo S. Carlino ; Catriona Mcneil ; Michal Lotem ; James Larkin ; Paul Lorigan ; Bart Neyns ; Christian Blank ; Teresa M. Petrella ; Omid Hamid ; Honghong Zhou ; Scot Ebbinghaus ; Nageatte Ibrahim ; Caroline Robert | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). |
| 000545 (2017) |
Jean-Pierre Delord ; Caroline Robert ; Marta Nyakas ; Grant A. Mcarthur ; Ragini Kudchakar ; Amit Mahipal ; Yasuhide Yamada ; Ryan Sullivan ; Ana Arance ; Richard F. Kefford ; Matteo S. Carlino ; Manuel Hidalgo ; Carlos Gomez-Roca ; Daniela Michel ; Abdelkader Seroutou ; Vassilios Aslanis ; Giordano Caponigro ; Darrin D. Stuart ; Laure Moutouh-De Parseval ; Tim Demuth ; Reinhard Dummer | Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. |
| 000627 (2017) |
Selma Ugurel ; Joachim Röhmel ; Paolo A. Ascierto ; Keith T. Flaherty ; Jean Jacques Grob ; Axel Hauschild ; James Larkin ; Georgina V. Long ; Paul Lorigan ; Grant A. Mcarthur ; Antoni Ribas ; Caroline Robert ; Dirk Schadendorf ; Claus Garbe | Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. |
| 000642 (2017) |
Dirk Schadendorf ; Georgina V. Long ; Daniil Stroiakovski ; Boguslawa Karaszewska ; Axel Hauschild ; Evgeny Levchenko ; Vanna Chiarion-Sileni ; Jacob Schachter ; Claus Garbe ; Caroline Dutriaux ; Helen Gogas ; Mario Mandalà ; John B A G. Haanen ; Céleste Lebbé ; Andrzej Mackiewicz ; Piotr Rutkowski ; Jean-Jacques Grob ; Paul Nathan ; Antoni Ribas ; Michael A. Davies ; Ying Zhang ; Mathilde Kaper ; Bijoyesh Mookerjee ; Jeffrey J. Legos ; Keith T. Flaherty ; Caroline Robert | Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. |
| 000975 (2017) |
Michael A. Davies ; Philippe Saiag ; Caroline Robert ; Jean-Jacques Grob ; Keith T. Flaherty ; Ana Arance ; Vanna Chiarion-Sileni ; Luc Thomas ; Thierry Lesimple ; Laurent Mortier ; Stergios J. Moschos ; David Hogg ; Iván Márquez-Rodas ; Michele Del Vecchio ; Céleste Lebbé ; Nicolas Meyer ; Ying Zhang ; Yingjie Huang ; Bijoyesh Mookerjee ; Georgina V. Long | Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. |
| 000D14 (2017) |
Paolo A. Ascierto ; Michele Del Vecchio ; Caroline Robert ; Andrzej Mackiewicz ; Vanna Chiarion-Sileni ; Ana Arance ; Céleste Lebbé ; Lars Bastholt ; Omid Hamid ; Piotr Rutkowski ; Catriona Mcneil ; Claus Garbe ; Carmen Loquai ; Brigitte Dreno ; Luc Thomas ; Jean-Jacques Grob ; Gabriella Liszkay ; Marta Nyakas ; Ralf Gutzmer ; Joanna Pikiel ; Florent Grange ; Christoph Hoeller ; Virginia Ferraresi ; Michael Smylie ; Dirk Schadendorf ; Laurent Mortier ; Inge Marie Svane ; Delphine Hennicken ; Anila Qureshi ; Michele Maio | Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. |
| 000F57 (2017) |
Jeffrey S. Weber ; F Stephen Hodi ; Jedd D. Wolchok ; Suzanne L. Topalian ; Dirk Schadendorf ; James Larkin ; Mario Sznol ; Georgina V. Long ; Hewei Li ; Ian M. Waxman ; Joel Jiang ; Caroline Robert | Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. |
| 001430 (2016) |
Adil I. Daud ; Jedd D. Wolchok ; Caroline Robert ; Wen-Jen Hwu ; Jeffrey S. Weber ; Antoni Ribas ; F Stephen Hodi ; Anthony M. Joshua ; Richard Kefford ; Peter Hersey ; Richard Joseph ; Tara C. Gangadhar ; Roxana Dronca ; Amita Patnaik ; Hassane Zarour ; Charlotte Roach ; Grant Toland ; Jared K. Lunceford ; Xiaoyun Nicole Li ; Kenneth Emancipator ; Marisa Dolled-Filhart ; S Peter Kang ; Scot Ebbinghaus ; Omid Hamid | Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. |
| 001501 (2016) |
Georgina V. Long ; Jean-Jacques Grob ; Paul Nathan ; Antoni Ribas ; Caroline Robert ; Dirk Schadendorf ; Stephen R. Lane ; Carmen Mak ; Philippe Legenne ; Keith T. Flaherty ; Michael A. Davies | Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. |
| 001F49 (2016) |
F Stephen Hodi ; Wen-Jen Hwu ; Richard Kefford ; Jeffrey S. Weber ; Adil Daud ; Omid Hamid ; Amita Patnaik ; Antoni Ribas ; Caroline Robert ; Tara C. Gangadhar ; Anthony M. Joshua ; Peter Hersey ; Roxana Dronca ; Richard Joseph ; Darcy Hille ; Dahai Xue ; Xiaoyun Nicole Li ; S Peter Kang ; Scot Ebbinghaus ; Andrea Perrone ; Jedd D. Wolchok | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. |
| 001F75 (2016) |
Antoni Ribas ; Omid Hamid ; Adil Daud ; F Stephen Hodi ; Jedd D. Wolchok ; Richard Kefford ; Anthony M. Joshua ; Amita Patnaik ; Wen-Jen Hwu ; Jeffrey S. Weber ; Tara C. Gangadhar ; Peter Hersey ; Roxana Dronca ; Richard W. Joseph ; Hassane Zarour ; Bartosz Chmielowski ; Donald P. Lawrence ; Alain Algazi ; Naiyer A. Rizvi ; Brianna Hoffner ; Christine Mateus ; Kevin Gergich ; Jill A. Lindia ; Maxine Giannotti ; Xiaoyun Nicole Li ; Scot Ebbinghaus ; S Peter Kang ; Caroline Robert | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. |
| 002513 (2016) |
Selma Ugurel ; Joachim Röhmel ; Paolo A. Ascierto ; Keith T. Flaherty ; Jean Jacques Grob ; Axel Hauschild ; James Larkin ; Georgina V. Long ; Paul Lorigan ; Grant A. Mcarthur ; Antoni Ribas ; Caroline Robert ; Dirk Schadendorf ; Claus Garbe | Survival of patients with advanced metastatic melanoma: The impact of novel therapies. |
| 002830 (2015) |
Jean Jacques Grob ; Mayur M. Amonkar ; Boguslawa Karaszewska ; Jacob Schachter ; Reinhard Dummer ; Andrzej Mackiewicz ; Daniil Stroyakovskiy ; Kamil Drucis ; Florent Grange ; Vanna Chiarion-Sileni ; Piotr Rutkowski ; Mikhail Lichinitser ; Evgeny Levchenko ; Pascal Wolter ; Axel Hauschild ; Georgina V. Long ; Paul Nathan ; Antoni Ribas ; Keith Flaherty ; Peng Sun ; Jeffrey J. Legos ; Diane Opatt Mcdowell ; Bijoyesh Mookerjee ; Dirk Schadendorf ; Caroline Robert | Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. |
| 002A58 (2015) |
Antoni Ribas ; Igor Puzanov ; Reinhard Dummer ; Dirk Schadendorf ; Omid Hamid ; Caroline Robert ; F Stephen Hodi ; Jacob Schachter ; Anna C. Pavlick ; Karl D. Lewis ; Lee D. Cranmer ; Christian U. Blank ; Steven J. O'Day ; Paolo A. Ascierto ; April K S. Salama ; Kim A. Margolin ; Carmen Loquai ; Thomas K. Eigentler ; Tara C. Gangadhar ; Matteo S. Carlino ; Sanjiv S. Agarwala ; Stergios J. Moschos ; Jeffrey A. Sosman ; Simone M. Goldinger ; Ronnie Shapira-Frommer ; Rene Gonzalez ; John M. Kirkwood ; Jedd D. Wolchok ; Alexander Eggermont ; Xiaoyun Nicole Li ; Wei Zhou ; Adriane M. Zernhelt ; Joy Lis ; Scot Ebbinghaus ; S Peter Kang ; Adil Daud | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. |
| 002B08 (2015) |
Georgina V. Long ; Daniil Stroyakovskiy ; Helen Gogas ; Evgeny Levchenko ; Filippo De Braud ; James Larkin ; Claus Garbe ; Thomas Jouary ; Axel Hauschild ; Jean-Jacques Grob ; Vanna Chiarion-Sileni ; Celeste Lebbe ; Mario Mandalà ; Michael Millward ; Ana Arance ; Igor Bondarenko ; John B A G. Haanen ; Johan Hansson ; Jochen Utikal ; Virginia Ferraresi ; Nadezhda Kovalenko ; Peter Mohr ; Volodymr Probachai ; Dirk Schadendorf ; Paul Nathan ; Caroline Robert ; Antoni Ribas ; Douglas J. Demarini ; Jhangir G. Irani ; Suzanne Swann ; Jeffrey J. Legos ; Fan Jin ; Bijoyesh Mookerjee ; Keith Flaherty | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. |
| 002D73 (2015) |
Dirk Schadendorf ; Mayur M. Amonkar ; Daniil Stroyakovskiy ; Evgeny Levchenko ; Helen Gogas ; Filippo De Braud ; Jean-Jacques Grob ; Igor Bondarenko ; Claus Garbe ; Celeste Lebbe ; James Larkin ; Vanna Chiarion-Sileni ; Michael Millward ; Ana Arance ; Mario Mandalà ; Keith T. Flaherty ; Paul Nathan ; Antoni Ribas ; Caroline Robert ; Michelle Casey ; Douglas J. Demarini ; Jhangir G. Irani ; Gursel Aktan ; Georgina V. Long | Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. |
| 003013 (2015) |
Dalil Hannani ; Marie Vétizou ; David Enot ; Sylvie Rusakiewicz ; Nathalie Chaput ; David Klatzmann ; Melanie Desbois ; Nicolas Jacquelot ; Nadège Vimond ; Salem Chouaib ; Christine Mateus ; James P. Allison ; Antoni Ribas ; Jedd D. Wolchok ; Jianda Yuan ; Philip Wong ; Michael Postow ; Andrzej Mackiewicz ; Jacek Mackiewicz ; Dirk Schadendorff ; Dirk Jaeger ; Inka Zörnig ; Jessica Hassel ; Alan J. Korman ; Keith Bahjat ; Michele Maio ; Luana Calabro ; Michele Wl Teng ; Mark J. Smyth ; Alexander Eggermont ; Caroline Robert ; Guido Kroemer ; Laurence Zitvogel | Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. |
| 003110 (2015) |
Paul Lorigan ; Paolo A. Ascierto ; Reinhard Dummer ; Alexander M. Eggermont ; Keith T. Flaherty ; Claus Garbe ; Helen Gogas ; Axel Hauschild ; Richard F. Kefford ; John M. Kirkwood ; James Larkin ; Georgina V. Long ; Michele Maio ; Grant A. Mcarthur ; Antoni Ribas ; Caroline Robert ; Dirk Schadendorf ; Vernon K. Sondak ; Jedd D. Wolchok ; Andrew M. Hudson | Expanded access programmes: patient interests versus clinical trial integrity. |
